Literature DB >> 10679588

[Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors].

F Longo1, X Hebuterne, A Tran, P Staccini, P Hastier, S Schneider, S Benzaken, C Tirtaine, P Rampal.   

Abstract

OBJECTIVES: To estimate the prevalence of viral hepatitis C markers and to determine independent risk factors in a population of patients with inflammatory bowel disease.
METHODS: We studied 117 consecutive out-patients (male/female, 53/64; mean age 41 +/- 16 yrs) with ulcerative colitis (43 patients) or Crohn's disease (74 patients). Anti-hepatitis C virus antibodies were tested with a third generation Elisa test. The following risk factors were tested for each patient: duration of inflammatory bowel disease, number of colonoscopies, history of surgical procedures, blood transfusions, intravenous drug abuse and immunosuppressive treatments.
RESULTS: The seroprevalence of hepatitis C virus was 5.98% (7/117). The only risk factor independently associated with serological markers for hepatitis C virus was blood transfusion (odds ratio: 7.77; confidence interval: 95% (1.63-49.09); P=0.012).
CONCLUSIONS: The prevalence of hepatitis C virus infection was high in patients with inflammatory bowel disease, mainly due to blood transfusions. Colonoscopies and surgical procedures were not found to be additional risk factors for infection with hepatitis C virus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10679588

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  8 in total

Review 1.  What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?

Authors:  Gianluca Andrisani; Alessandro Armuzzi; Manuela Marzo; Carla Felice; Daniela Pugliese; Alfredo Papa; Luisa Guidi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

Review 2.  Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis.

Authors:  Pilar López-Serrano; Jose Lázaro Pérez-Calle; Maria Dolores Sánchez-Tembleque
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

3.  Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementino Fraga Filho university hospital.

Authors:  Yolanda Faia Manhaes Tolentino; Homero Soares Fogaca; Cyrla Zaltman; Lia Laura Lewis Ximenes; Henrique Sergio Moraes Coelho
Journal:  World J Gastroenterol       Date:  2008-05-28       Impact factor: 5.742

Review 4.  Hepatitis C virus and inflammatory bowel disease.

Authors:  Todd L Horn; Joel Reynolds; Willem de Villiers; Luis R Peña
Journal:  Dig Dis Sci       Date:  2008-10-31       Impact factor: 3.199

Review 5.  The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease.

Authors:  Ming Valerie Lin; Wojciech Blonski; Anna M Buchner; K Rajender Reddy; Gary R Lichtenstein
Journal:  Dig Dis Sci       Date:  2012-11-20       Impact factor: 3.199

6.  Prevalence of hepatitis B, hepatitis C and human immunodeficiency viral infections in patients with inflammatory bowel disease in north India.

Authors:  Parnita Harsh; Vipin Gupta; Saurabh Kedia; Sawan Bopanna; Sucharita Pilli; Govind Kumar Makharia; Vineet Ahuja
Journal:  Intest Res       Date:  2017-01-31

Review 7.  Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver.

Authors:  Loris Riccardo Lopetuso; Giammarco Mocci; Manuela Marzo; Francesca D'Aversa; Gian Lodovico Rapaccini; Luisa Guidi; Alessandro Armuzzi; Antonio Gasbarrini; Alfredo Papa
Journal:  Int J Mol Sci       Date:  2018-07-27       Impact factor: 5.923

Review 8.  Core indicators of an evaluation and guidance system for quality of care in inflammatory bowel disease centers: A critical review.

Authors:  Yueying Chen; Jun Shen
Journal:  EClinicalMedicine       Date:  2022-04-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.